Over the past decade, mucoadhesive polymers have gained increasing attention as key enablers in the development of advanced drug delivery systems for brain therapies. Among them, hyaluronic acid (HA) stands out for its exceptional tunability, biocompatibility and processability, positioning it as a highly promising candidate for the treatment of central nervous systems (CNS) disorders across multiple administration routes (i.e. parenteral, intranasal, oral). Current discoveries in material science and pharmaceutic formulations offer the chance to design HA based transformative carriers for brain delivery and targeting, promoting a receptor-specific uptake and precise modulation of therapeutic responses within the CNS. Herein, recent advances in the design of HA-based platforms for brain drug delivery were critically examined with a particular focus on emerging strategies for HA synthesis, functionalization and processing. By integrating advanced carrier design to innovative strategies of molecular targeting, HA based systems can enhance brain accumulation, improve safety profiles and unlock multimodal treatments. HA based platforms open new avenues to enhance drug targeting, therapeutic efficacy, and overall patient outcomes. Future challenge will be to overcome manufacturing, scalability, and translational barriers to translate this powerful platform from preclinical promise to clinical reality.
Obesity is a multifactorial disease associated with a chronic imbalance between energy intake and energy consumption, as well as the ingestion of high-fat foods. It is widely reported that the Mediterranean Diet (MD), a dietary regimen rich in vegetables, fruits, fiber and complex polyunsaturated lipids, can positively act on obesity onset. These aliments contain bioactive molecules that exert beneficial effects on two traits often associated with obesity: lipid accumulation and imbalance in oxidative homeostasis. Additionally, they can act on metabolic pathways linked to obesity through the cross-kingdom activity of plant miRNAs. In this review, we provide an overview of the studies describing the anti-obesogenic effect of plant-based foods typical of the Mediterranean Diet. We describe the results of recent studies that link the effect of lipid reduction with the ingestion of bioactive molecules or plant miRNAs typical of MD foods. We also report how advances in bioinformatic analyses have elucidated the role of plant-derived miRNAs in metabolic homeostasis, revealing how the cross-kingdom interaction results in the anti-obesogenic action of the MD. These findings shed light on the molecular mechanisms through which the MD dietary pattern exerts its metabolic effects, suggesting new perspectives on MD nutrition-based strategies as novel therapeutic approaches for obesity.